Idiopathic Pulmonary Fibrosis News and Research

RSS
Pulmonary fibrosi is a condition in which tissue deep in your lungs becomes thick and stiff, or scarred, over time. The development of the scarred tissue is called fibrosis. As the lung tissue becomes thicker, your lungs lose their ability to move oxygen into your bloodstream. As a result, your brain and other organs don't get the oxygen they need.

In some cases, doctors can find out what's causing the fibrosis. But in most cases, they can't find a cause. They call these cases idiopathic pulmonary fibrosis (IPF). IPF is a serious condition. About 200,000 Americans have it. About 50,000 new cases are diagnosed each year. IPF mostly affects people who are 50 to 75 years of age. IPF varies from person to person. In some people, the lung tissue quickly becomes thick and stiff. In others, the process is much slower. In some people, the condition stays the same for years. IPF has no cure yet. Many people live only about 3 to 5 years after diagnosis. The most common cause of death related to IPF is respiratory failure.
IQWiG publishes report on Esbriet benefit assessment for treatment of IPF

IQWiG publishes report on Esbriet benefit assessment for treatment of IPF

Insights into causes of Idiopathic Pulmonary Fibrosis

Insights into causes of Idiopathic Pulmonary Fibrosis

Ligand third quarter total revenues decrease to $5.7 million

Ligand third quarter total revenues decrease to $5.7 million

Promedior's Pentraxin-2 effectively suppresses liver fibrosis

Promedior's Pentraxin-2 effectively suppresses liver fibrosis

Blood biomarker panel can predict survival in IPF patients

Blood biomarker panel can predict survival in IPF patients

European CHMP adopts positive opinion for Pharmaxis Bronchitol Marketing Authorisation

European CHMP adopts positive opinion for Pharmaxis Bronchitol Marketing Authorisation

NIH stops triple-drug therapy clinical trial for idiopathic pulmonary fibrosis

NIH stops triple-drug therapy clinical trial for idiopathic pulmonary fibrosis

Coughing may signal trouble for patients with idiopathic pulmonary fibrosis

Coughing may signal trouble for patients with idiopathic pulmonary fibrosis

PFF establishes Research Fund to Cure Pulmonary Fibrosis

PFF establishes Research Fund to Cure Pulmonary Fibrosis

Simmons Center to evaluate CGEN-25009 for treatment of idiopathic pulmonary fibrosis

Simmons Center to evaluate CGEN-25009 for treatment of idiopathic pulmonary fibrosis

InterMune reports new data from Esbriet clinical trial on IPF

InterMune reports new data from Esbriet clinical trial on IPF

Bortezomib drug may also treat pulmonary fibrosis or scleroderma

Bortezomib drug may also treat pulmonary fibrosis or scleroderma

NEJM publishes Boehringer Ingelheim's BIBF 1120 phase II trial on IPF

NEJM publishes Boehringer Ingelheim's BIBF 1120 phase II trial on IPF

Enrollment commences in Boehringer Ingelheim's TOviTO Phase III combination trial for COPD

Enrollment commences in Boehringer Ingelheim's TOviTO Phase III combination trial for COPD

InterMune to launch Esbriet for German patients with IPF

InterMune to launch Esbriet for German patients with IPF

Bristol-Myers Squibb acquires Amira Pharmaceuticals

Bristol-Myers Squibb acquires Amira Pharmaceuticals

Double-lung transplant survivor stays busy since retirement

Double-lung transplant survivor stays busy since retirement

Celgene reports second quarter total revenue of $1.18 billion

Celgene reports second quarter total revenue of $1.18 billion

Bristol-Myers Squibb signs definitive agreement to acquire Amira Pharmaceuticals

Bristol-Myers Squibb signs definitive agreement to acquire Amira Pharmaceuticals

Gastroespophageal reflux treatment might improve survival in patients with IPF

Gastroespophageal reflux treatment might improve survival in patients with IPF

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.